In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans

Drug Metabolism and Disposition

Volumn 27, Issue 2, 1999, Pages 240-245

  Calabrese, C R ^a   Loadman, Paul M ^a   Lim, L S E ^a   Bibby, M C ^a   Double, J A ^a   Brown, J E ^a   Lamb, J H ^b  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b MRC TOXICOLOGY UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMIDACRINE; IMIDAZOACRIDINONE DERIVATIVE; M 1; M 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DRUG DISTRIBUTION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG TISSUE LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMINOACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; FEMALE; GLUCURONIDASE; HALF-LIFE; HUMANS; MALE; MASS SPECTROMETRY; MICE; MICROSOMES, LIVER;

ANIMALIA; MURINAE;

EID: 0032913055     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Alberts DS, Peng Y-M. Bowden GT, Dalton WS and Mackel C (1985) Pharmacology of mitoxantrone: Mode of action and pharmacokinetics. Invest New Drugs 3:101-107.
2. Batra VK, Morrison JA, Woodward DL, Siverd NS and Yacobi A (1986) Pharmacokinetics of mitoxantrone in man and laboratory animals. Drug Metab Rev 17:311-329.
3. Berger B, Marquardt H and Westendorf J (1996) Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents. Cancer Res 56:2094-2104.
4. Blanz J, Mewes K, Ehninger G, Proksch B, Waidelich D, Greger B and Zeller K-P (1991) Evidence for oxidative activation of mitoxantrone in human, pig and rat. Drug Metab Disp 19:871-880.
5. Burger AM, Double JA, Konopa J and Bibby MC (1996) Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer. Br J Cancer 74:1369-1374.
6. Calabrese CR, Bibby MC, Double JA and Loadman PM (1998) Pharmacokinetics and tissue distribution of the imidazoacridinone C1311 in tumour bearing mice. Cancer Chemother Pharmacol 42:379-385.
7. Calabrese CR and Loadman PM (1997) Analysis of the imidazoacridinone C1311 by high performance liquid chromatography. J Chromatogr 690:275-281.
8. Chiccarelli FS, Morrison JA, Cosulich DB, Perkinson NA and Ridge DN (1986) Identification of human urinary mitoxantrone metabolites. Cancer Res 46:4858-4861.
9. Cholody WM, Martelli S, Paradziej-Lukowicz J and Konopa J (1990) 5-[(Aminoalkyl)amino] imidazo[4,5,1-de] acridin-6-ones as a novel class of antineoplastic agents. Synthesis and biological activity. J Med Chem 33:49-52.
10. Dolfini E, Martini A, Donelli MG, Morasca L and Garattini S (1973) Method for tissue culture evaluation of the cytotoxic activity of drugs active through the formation of metabolites. Eur J Cancer 9:375-378.
11. Double JA and Cifuentes de Castro L (1978) Chemotherapy of transplantable adenocarcinomas of the colon in mice. Cancer Treat Rep 62:85-90.
12. Jabbar SAB, Twentyman PR and Watson JV (1989) The MTT assay underestimates the growth inhibitory effects of interferons. Br J Cancer 60:523-528.
13. Kroemer HK and Klotz U (1992) Glucuronidalion of drugs: A re-valuation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmcokinet 23:292-310.
14. Kusnierczyk H, Cholody WM, Paradziej-Lukowicz J. Radzikowski C and Konopa J (1994) Experimental antitumour activity and toxicity of the selected triazolo-and imidazoacridinones. Arch Immunol Ther Exp 42:415-423.
15. Macpherson JS, Smyth JF, Clements JA, Ramsay MW, Warrington PS, Leonard RCF and Wolf CR (1984) Pharmacokinetics and metabolism of mitoxantrone. Br J Cancer 50:252-253.
16. Mazerska Z, Augustin E, Dziegielewski J, Cholody WM and Konopa J (1996) QSAR of acridines III. Structure-activity relationship for antitumor imidazoacridinones and intercorrelations between in vivo and in vitro tests. Anticancer Drug Des 11:73-88.
17. Phillips RM, Hulbert PB, Bibby MC, Sleigh NR and Double JA (1992) In vitro activity of the novel inodloquinone EO9 and the influence of pH on cytotoxicity. Br J Cancer 65:359-364.
18. Skladanowski A, Plisov SY, Konopa J and Larsen AK (1996) Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Mol Pharmacol 49:772-780.
19. Warr JR, Quinn DM, Double JA and Bibby MC (1997) Low level multidrug resistance expression to C1311, a potential clinical candidate. Br J Cancer 75 (Suppl 1):33.
20. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T and Wallace J (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 77:1-10.